REVIEW
Published on 07 Aug 2024
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia
doi 10.3389/fcvm.2024.1389106
- 2,371 views
- 3 citations
- Frontiers in Cardiovascular Medicine
- Cardiovascular Pharmacology and Drug Discovery
- Research Topics
- Therapeutic Strategies to Lower Residual Dyslipidemic CV Risk Beyond LDL-C and Statins
Therapeutic Strategies to Lower Residual Dyslipidemic CV Risk Beyond LDL-C and Statins
4,568
Total downloads
18k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
MINI REVIEW
Published on 13 Mar 2024
Effect of statin add-on therapy on cardiovascular mortality
doi 10.3389/fcvm.2024.1308695
- 2,103 views
REVIEW
Published on 15 Jan 2024
Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins
doi 10.3389/fcvm.2023.1308173
- 1,859 views
REVIEW
Published on 31 Aug 2023
Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
doi 10.3389/fcvm.2023.1220017
- 3,538 views
- 1 citation
ORIGINAL RESEARCH
Published on 23 Aug 2023
Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events
doi 10.3389/fcvm.2023.1229130
- 4,083 views
- 7 citations
ORIGINAL RESEARCH
Published on 03 Aug 2023
Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE
doi 10.3389/fcvm.2023.1204071
- 2,255 views
- 4 citations
Published in
Frontiers in Cardiovascular Medicine
- Cardiovascular Pharmacology and Drug Discovery
Impact
- 18kTopic views
- 13kArticle views
- 4,568Article downloads